Literature DB >> 31784881

Efficacy of low radioiodine activity versus intermediate-high activity in the ablation of low-risk differentiated thyroid cancer.

Domenico Albano1,2, Mattia Bonacina3, Rexhep Durmo3, Francesco Bertagna4, Raffaele Giubbini4.   

Abstract

PURPOSE: The aim of our study was to compare the efficacy of thyroid remnant ablation using low (1.1 GBq) and intermediate-high radioiodine (RAI) activity (1.85-3.7 GBq) in low-risk differentiated thyroid carcinoma (DTC) and to evaluate the staging role of the whole body scan (WBS) in detection extrathyroidal disease.
MATERIALS AND METHODS: We retrospectively included 277 patients who underwent total thyroidectomy and RAI for low-risk DTC and divided them in two groups according to RAI activity at ablation: group 1 (n = 174) treated with low activity (1.1 GBq), and group 2 (n = 103) with intermediate-high activity (1.85-3.7 GBq). To evaluate the successful ablation rate, the WBS 1 year after RAI was visually interpreted using a three-point scale: score 0 in case of absence of visible RAI uptake in thyroid bed; score 1 in presence of faint uptake in the thyroid bed; and score 2 in case of significant RAI uptake in thyroid bed.
RESULTS: The success ablation rate was significantly higher in group 2 than group 1 (p < 0.001) with the presence of a positive WBS (score 1-2) in 65% low-activity group and 33% in intermediate-high group. Considering response to therapy categories, excellent response rate was significantly higher in group 2 (p = 0.020), while indeterminate response was higher in group 1 (p value = 0.005). Post RAI imaging revealed extrathyroidal uptake in 27 cases: 17 laterocervical nodal and 10 distant metastases. In both groups similar detection rate of nodal and distant metastases were recognized without any statistical difference.
CONCLUSIONS: The ablation rate with intermediate-high RAI activity (1.85-3.7 GBq) was better than with a low activity (1.1 GBq). First WBS may help to recognize nodal and distant metastases in about 10% of cases changing clinical stage and subsequent management.

Entities:  

Keywords:  Ablation; Differentiated thyroid cancer; RAI; Staging

Mesh:

Substances:

Year:  2019        PMID: 31784881     DOI: 10.1007/s12020-019-02148-9

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  1 in total

1.  Different features of pulmonary metastases in differentiated thyroid cancer: natural history and multivariate statistical analysis of prognostic variables.

Authors:  D Casara; D Rubello; G Saladini; G Masarotto; A Favero; M E Girelli; B Busnardo
Journal:  J Nucl Med       Date:  1993-10       Impact factor: 10.057

  1 in total
  6 in total

1.  Assessing potential impact of 2015 American Thyroid Association guidelines on community standard practice for I-131 treatment of low-risk differentiated thyroid cancer: case study of Jordan.

Authors:  Malik E Juweid; Nidal J Rabadi; Mark Tulchinsky; Mohammed Aloqaily; Ahmad Al-Momani; Majd Arabiat; Gassem Abu Ain; Hussam Al Hawari; Munther Al-Momani; Ayman Mismar; Amr Abulaban; Ibrahim Taha; Abdullah Alhouri; Ayman Zayed; Nader Albsoul; Mousa A Al-Abbadi
Journal:  Endocrine       Date:  2021-03-27       Impact factor: 3.633

2.  Retrospective Analysis of the Development of Human Thyroglobulin during Pregnancy in Patients with Treated Non-Recurrent Differentiated Thyroid Cancer.

Authors:  Justus Baumgarten; Christian Happel; Daniel Groener; Jennifer Staudt; Benjamin Bockisch; Amir Sabet; Frank Grünwald; Thomas Rink
Journal:  Curr Oncol       Date:  2022-05-31       Impact factor: 3.109

3.  Value of stimulated pre-ablation thyroglobulin as a prognostic marker in patients with differentiated thyroid carcinoma treated with radioiodine.

Authors:  Giulliana Nóbrega; Milena Cavalcanti; Verônica Leite; Lúcio Vilar; Simone Cristina Soares Brandão
Journal:  Endocrine       Date:  2022-03-02       Impact factor: 3.925

4.  Prognostic Role of 2-[18F]FDG PET/CT Metabolic Volume Parameters in Patients Affected by Differentiated Thyroid Carcinoma with High Thyroglobulin Level, Negative 131I WBS and Positive 2-[18F]-FDG PET/CT.

Authors:  Domenico Albano; Francesco Dondi; Angelica Mazzoletti; Pietro Bellini; Carlo Rodella; Francesco Bertagna
Journal:  Diagnostics (Basel)       Date:  2021-11-25

5.  The role of Tg kinetics in predicting 2-[18F]-FDG PET/CT results and overall survival in patients affected by differentiated thyroid carcinoma with detectable Tg and negative 131I-scan.

Authors:  Domenico Albano; Mark Tulchinsky; Francesco Dondi; Angelica Mazzoletti; Francesco Bertagna; Raffaele Giubbini
Journal:  Endocrine       Date:  2021-05-20       Impact factor: 3.633

6.  The role of Hashimoto thyroiditis in predicting radioiodine ablation efficacy and prognosis of low to intermediate risk differentiated thyroid cancer.

Authors:  Domenico Albano; Francesco Dondi; Valentina Zilioli; Maria Beatrice Panarotto; Alessandro Galani; Carlo Cappelli; Francesco Bertagna; Raffaele Giubbini; Claudio Casella
Journal:  Ann Nucl Med       Date:  2021-06-21       Impact factor: 2.668

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.